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Summary Natural killer (NK) cell activity and lymphokine activated killer (LAK) cell cytotoxicity were
measured in patients receiving recombinant interleukin 2 (rIL-2) and flavone acetic acid (FAA) for treatment
of progressing metastatic melanoma. NK activity was increased in 23 of 26 patients and LAK activity induced
in 13 of 26 patients. However, levels of cytotoxicity in the present study were not significantly greater than a
previous study using rIL-2 alone. LAK cell precursors demonstrated by in vitro incubation of pretreatment
lymphocytes with IL-2 and subsequent cytotoxicity were no different in the patients compared to normal
controls. Analysis of cell surface phenotypes failed to reveal any significant changes in the cell populations
examined, including IL-2R and Leu 19. Although five patients had tumour response, one being complete, there
was no correlation with the immunological parameters examined.
Several studies have shown that the administration of
interleukin 2, either alone or in conjunction with broadly
cytotoxic lymphokine activated killer cells (LAK) generated
by in vitro co-culture with IL-2 have resulted in tumour
regression in a range of established human tumours including
melanoma (Rosenberg et al., 1987; Rosenberg, 1988; West et
al., 1987; Hank et al., 1988). This combined adoptive
immunotherapy is, however, expensive and labour intensive,
and toxicity is severe when high doses of IL-2 are used. In
our previous phase I/II clinical trial of intrasplenic and intra-
venous rIL-2 less toxicity was achieved and partial clinical
responses were observed in 15% of patients with progressing
advanced melanoma (Thatcher et al., 1989). These encou-
raging results stimulated interest in using rIL-2 in combina-
tion with other biological response modifiers or with
chemotherapeutic drugs in the hope that better clinical re-
sponses could be achieved.
Flavone acetic acid (FAA) is a synthetic flavonoid found
to have an antitumour effect against a spectrum of murine
solid tumours and to augment natural killer cell activity in
spleen and other tissues in normal mice (Finlay et al., 1988;
Zaharko et al., 1986; Ching & Baguley, 1987). This suggested
that FAA may act as a biological response modifier as well
as functioning as a chemotherapeutic drug. NK cells have
been shown to be the major effector cell population con-
tributing to the generation of LAK activity by rIL-2 (Itoh et
al., 1985; Ferrini et al., 1987; Herberman et al., 1987).
Preliminary studies by Wiltrout et al. (1988) showed that
FAA synergised with rIL-2 in the treatment of murine renal
cancer. Further studies showed that this synergy was due to
augmentation of natural killer cell activity, induction of IFN
ct/p and induction of long lasting tumour immunity (Hornung
et al., 1988a, b).
On the basis of these properties of FAA, a phase II clinical
trial of FAA in combination with intrasplenic and intra-
venous rIL-2 was initiated in patients with progressing malig-
nant melanoma and in this report the immunological
responses that resulted from this treatment are described.
Materials and methods
Patients
Thirty-four patients (19 male and 15 female) with progressive
metastatic melanoma were entered into this study. Nine
patients had undergone previous DTIC melphalan with or
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without local radiotherapy, although no patients had received
anti-tumour treatment 4 weeks before entry into the study.
Further clinical details from these patients are described
elsewhere (Thatcher et al., 1990).
Interleukin-2/flavone acetic acid administration
Recombinant IL-2 (kindly supplied by Eurocetus BV, Am-
sterdam) was administered as described previously by That-
cher et al. (1989). Briefly, the initial dose (intrasplenic) was
followed 4 h later by intravenous administration followed by
three alternate day i.v. doses. A maximum of three such
courses was given at 21-day intervals after the FAA adminis-
tration. The doses given (11 x 106 Cetus units mr2) were
taken from the preceding phase I/II study of rIL-2 alone
(Thatcher et al., 1989) and the median cumulative dose of
12.0 x 107 U m-2 was almost identical.
FAA was kindly supplied by Lipha, Lyon. The maximum
tolerated FAA dose has depended on the administration
schedule and it was decided that 4.8 g m-2 as a 6 h infusion
on the days preceding the rIL-2 doses was reasonable.
Alkalinisation of the urine by i.v. administration of 500 ml
1.26% sodium bicarbonate I h before and after the infusions
to prevent renal damage by FAA was also carried out.
Sample collection
Twenty ml of heparinised venous blood was collected
immediately before rIL-2 administration or every week
between IL-2/FAA courses and peripheral blood
mononuclear cells (PBMCs) were separated immediately on
lymphocyte separation medium (LSM) gradients. With
selected patients, blood was obtained immediately before
IL-2 administration and then I and 2 h post-administration.
Cytotoxicity assays
A 4 h 5'Cr release assay was used to test the cytotoxicity of
patients' PBMCs against the K562 erythroleukaemic cell line,
an NK sensitive target; the Daudi (Burkitt lymphoma) NK
resistant LAK sensitive cell line and the Mel 1, NK resistant,
LAK sensitive target orginating from a malignant melanoma.
PBMCs were assayed in triplicate at effector to target
ratios of between 80:1 and 5:1 with 2 x 104 5'CR labelled
targets per well. Spontaneous and maximum release values
were also calculated and a more detailed summary of this
method is given by Ghosh et al. (1989).
Activation ofLAKprecursors by IL-2 and FAA
The generation of LAK activity in vitro from PBMCs
stimulated for 5 days in 2ml wells (at a concentration of
Br. J. Cancer (1990), 61, 471-474 ("I Macmillan Press Ltd., 1990472 A.K. GHOSH et al.
1-2 x 106 ml 1) in 24-well plates with 200 IU ml' rIL-2 was
also assessed and compared with the cytotoxicity of LAK
precursor cells found in four normal donors.
Phenotype analysis ofPBMCs
Cytospins of patient PBMCs were made before and after
every stage of treatment and stained for various lymphocyte
markers with Mabs using the APAAP technique (Cordell et
al., 1984). The Mabs used were UCHTI (CD3), DAKO T4
(CD4), DAKO T8 (CD8), ACT-1 (CD25) reactive with the
IL-2 receptor, DAKO Leu 19 and the T cell Sciences TCR
Delta-1.
Percentages of cells staining for the different antibodies
were assessed by looking at four different fields of view from
the slide and taking the mean value. (Numbers of cells
counted ranged from 50 to 500 per field of view.)
Results
Clinical response
A complete report of the patients' clinical details is given
elsewhere (see Thatcher et al., 1990). Twenty-six of the 34
patients entered into the phase II trial were subjected to
immunological analysis and Table I summarises the clinical
response of the group studied for NK and LAK activity.
Cytotoxic activity ofPBMC in patients receiving FAA and
rIL-2 treatment
NK activity Ten of the 26 patients studied showed positive
cytotoxicity (greater than 10% lysis) against the cultured
K562 cell line before treatment with values ranging from 11
to 59%. In 23/26 patients significant increases in NK activity
were observed while receiving FAA/IL-2 treatment, ranging
from 2 to 20 times increase in cytotoxicity or from 12 to 91%
lysis. However, no specific trends could be determined in
subgroups of patients divided by their responses to treatment
(progression, stable or response). This is illustrated for four
patients in Figure 1. One of the patients whose disease
progressed (no. 22) showed augmented NK activity after the
second course of treatment, while another patient (no. 3)
showed similar levels of NK activity after the first two treat-
ment cycles. The patient who had a complete response
(no. 32) showed a dramatic increase in NK activity 14 days
after the commencement of the first treatment cycle, which
was not repeated after the second or third cycle. This graph
also highlights the common feature to all the patients in this
study; that the NK activity undergoes considerable fluctua-
tion.
LAK activity Only five of the 26 patients examined showed
low levels of pre-treatment cytotoxity with Mel-I (LAK sen-
sitive) targets with values ranging from 13 to 16% lysis. In
general, the cytotoxic activities were lower than those for
K562 targets (see Table I). LAK cytolytic activity was
observed, however, in 13 patients over the treatment period,
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Figure 1 Cytotoxicity against K562 in patients on FAA/IL-2
treatment (effector: target cell ratio was 50:1) patient no. 3, 22
progession; no. 31, partial response; no. 32, complete response.
with values ranging from II to 55%, indicating an increase
in activity from 2 to 22 times. The Daudi (LAK sensitive)
cell line was also used to investigate cytotoxic effects in seven
patients. Values were similar to the Mel-i results. The most
interesting finding, which seemed to parallel both the K562
and Mel-i results, was that of a dramatic increase in cytotox-
icity two weeks after the first course of FAA/IL-2 in the
patient who underwent a complete response (see Figure 2).
Indeed, the value for the Daudi cells was 99% (data not
shown), the highest value seen throughout these experiments.
The increases in LAK activity followed a similar time course
to that of NK activity with a peak during the first or second
weeks after FAA/IL-2 administration. Three patients who
had samples collected immediately before and 1 and 2 h after
IL-2 administration, showed that a decrease in LAK activity
occurred within 1 h of IL-2 administration (data not shown).
However, in two of the three the pre-treatment cytotoxicity
values were less than 10%.
LAK cell precursors
Pre-treatment PBMCs from 20 patients were stimulated with
200 IU m-' rIL-2 in vitro for 5 days and their NK and LAK
cell lytic activity were assayed and compared with four nor-
mal subjects. There was no difference in the cytotoxicities
assayed against K562, the NK sensitive cell line, but higher
cytotoxic values were obtained against Mel- and Daudi
targets in the patient group compared to controls (Table II).
The inducibility of LAK activity in vitro was determined on
day 7 after the first week of FAA and rIL-2 treatment in 13
patients. In nine patients there was augmentation of
cytotoxic capacity of PBMCs induced by IL-2 in vitro against
the Mel-i target, the highest increase from 41 to 79%. There
were small increases up to 10% cytotoxicity observed against
K562 in three patients after week of treatment.
Of the patients PBMC stimulated with rIL-2 in vitro, there
Table I Cytotoxic activity of PBMC from patients receiving IL-2/FAA against NK
sensitive and NK-resistant, LAK sensitive targets in relation to clinical response
Ex vivo effector cellfunction
NK LAK
Clinical No. positive Cytotoxicity No. positive Cytotoxicity
response No. cases range (%) No. cases range (%)
Progression 13/14 (5-76) 6/14 (1-50)
Stable 6/7 (7-73) 4/7 (2-30)
Partial response 3/4 (3-66) 2/4 (1-46)
Complete response 1/1 (2-91) 1/1 (1-55)
Cytotoxicity values showing any kind ofincrease with treatment and greater that 10%
were considered positive. All E:T ratios were at 50:1. A more detailed explanation ofthe
patient responses is given in the clinical appraisal of this trial (Thatcher et al., 1990).rIL-2 WITH FAA IN ADVANCED MALIGNANT MELANOMA 473
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Figure 2 Cytotoxicity against Mel-I in patients on FAA/IL-2
treatment (effector: target cell ratio was 50:1): patient no. 3, 22
progression; no. 31, partial response; no. 32, complete response.
Table II Cytotoxicity activity of PBMC from patient receiving rIL-2
and FAA and incubated in vitro with rIL-2 for 5 days
% cytotoxicity,
K562 Mel-1 Daudib
(4) 75 (51-87) 41 (23-55) 59 (28-77)
(20) pretreatment 78 (45-99) 55 (27-73) 76 (59-85) (I13) day 7 77 (36-97) 66 (36-81) n.d.
aMean cytotoxicity (range); bonly seven patients pre-treatment PBMC were assayed against Daudi cells. n.d., not determined.
was no significant difference in the cytotoxicity values
between those who progressed and those who responded or
stabilised with treatment.
Phenotypic analysis ofPBMCs
The expression of T cell antigens CD3, CD4 and CD8 did
not change significantly throughout treatment. Nineteen
patients were examined throughout their course ofFAA/IL-2 treatment for the IL-2 receptor. Percentages ofpositive cells
varied with a range from 0 to 34%. In general a slight increase I week after FAA/IL-2 administration was followed
by largely fluctuating values in the forthcoming weeks. In
most patients raised values were not maintained for any length of time. Eighteen patients were examined for Leu 19
positive cells with percentages of stained cells ranging from 0
to 36%. No obvious trends in Leu 19 expression correlating with the treatment course were detected or with elevation of
NK or LAK cell activity. Seven patients were examined for
the TCRy6 receptor, percentages of stained cells varying between 0 and 15%. Again no trends or patterns emerged.
Discussion
IL-2 can induce LAK cell activity in vitro and this property may account for its therapeutic value in vivo. LAK cell
precursors are a heterogenous lymphocyte population includ- ing NK cells and lymphocytes (Itoh et al., 1985). Any agent augmenting NK activity may therefore expect to synergise with the action of IL-2. FAA has been shown to have high anti-tumour activity and a possible host mediated mechanism oftoxicity including augmentation ofNK cell activity (Ching & Baguley, 1987; Wiltrout & Hornung, 1988). The current study of a phase II trial of rIL-2 and FAA in patients with metastatic melanoma has shown that this treatment can enhance NK activity in patients with advanced cancer. Twenty-three of 26 patients showed increases in NK activity usually 7-14 days after commencement of a FAA and IL-2
treatment cycle. As samples were predominantly obtained at weekly time intervals the time course of induction of NK activity could not be assessed. Urba et al.(1988) observed significant increases in NK activity within 72h of a 3 h
infusion of FAA in three of six patients with advanced
cancer. In our previous study of rIL-2 alone (Ghosh et al.,
1989), increased NK activity was observed in 16 of 20
patients while on treatment. Wiltrout et al. (1988) showed
maximal NK cell activity in the peripheral blood of mice at
48 h, which persisted for 6 days after FAA administration.
Administration of IL-2 with FAA augmented systemic NK
activity in renca tumour bearing mice 3-5-fold over that
obtained with FAA or rIL-2 alone. A significant increase of
NK activity with the combined treatment was not observed
in the current patients when compared with the previous
study of rIL-2 alone (Ghosh et al., 1989), although the
median levels of cytotoxicity were slightly higher. Again
LAK activity was induced in 50% of patients and compares
with 45% of patients in the previous IL-2 study. However,
levels ofcytotoxicity were not significantly greater than in the
previous study.
Murine models have shown that there is a dose response to
FAA for NK cell activation (Ching & Baguley, 1987) and
that lower doses may be more effective than high doses at
enhancing NK activity. As the FAA dose used in the study is
considered to be the highest that was clinically tolerable, it
may not have been the optimal dose to maximise its
immunological effects. The timing of FAA and administra-
tion of rIL-2 may also be important in achieving their syner-
gistic effect and the optimal conditions still need to be deter-
mined.
An anti-tumour effect may not be reflected in peripheral
blood NK activity and it may be more relevant to examine
the tumour infiltrating lymphocytes. Activated lymphocytes
have been observed at the site of tumours and can be
expanded in vitro with rIL-2 to produce both LAK cells and
specific T cell responses (Anderson et al., 1988; Ettinghausen
et al., 1985a,b). However, it would be necessary to obtain
tumour specimens before and after treatment to analyse the
TILs effectively, although this approach has practical limita-
tions.
The mode of action of FAA and rIL-2 in the treatment of
murine renal cancer has been investigated (Wiltrout et al.,
1988; Hornung et al., 1988a,b). FAA plus rIL-2 augmented
NK activity to a greater extent than FAA or rIL-2 alone,
which correlated with the enhanced anti-tumour activity. NK
cells may act directly on the tumour cells or via secondary
production of cytokines. IFN x/p induction has been de-
scribed in mice and humans after FAA administration (Urba
et al., 1988; Hornung et al., 1988) and IL-2 can also
induce cytokines. Thus these agents probably have pleio-
tropic biological effects, including direct anti-tumour effects
and an indirect mode of action (Wiltrout & Hornung,
1988b). Preliminary in vitro studies (unpublished observations
from our laboratory) failed to detect augmentation of NK
activity or LAK cytotoxicity by FAA alone (dose range
100-1,000 lg ml-') or in combination with rIL-2, suggesting
that metabolites of FAA may be responsible for some of the
indirect BRM-mediated anti-tumour effects of FAA in vivo.
Higher doses of FAA also appeared to have an inhibitory
effect on NK activity and on LAK cell induction by rIL-2.
These in vitro observations are in agreement with other
studies (Wiltrout & Hornung, 1988) and the dose effect was
observed in vivo in mice in a study by Ching and Baguley
(1988).
The combined treatment of FAA and rIL-2 did not have
any conclusive effect on the phenotype of peripheral blood
lymphocytes. The large increase in IL-2R positive cells
observed in the previous study of IL-2 alone was not
observed although small increases did occur. This result is
surprising because in vitro treatment with IL-2 results in large
increases in IL-2R positive cells and Leu 19 cells. Circulating
Leu 19+cells were shown to be the effector cell population
responsible for LAK activity in patients on IL-2 treatment
(McMannis et al., 1988) and as LAK cytotoxicity was dem-
onstrated in a number of these patients, one might expect a
parallel increase in Leu 19+cells. It is possible that FAA
might suppress these cells and is to be investigated.
Although animal models have indicated that combined474 A.K. GHOSH et al.
FAA and rIL-2 administration have a greatly enhanced anti-
tumour effect than either agent alone, the present clinical
study showed only a slightly improved response rate com-
pared to rIL-2 alone. This highlights the difficulty in trans-
lation of pre-clinical animal experimental trials into clinical
treatment of patients. The patients were all capable of re-
sponding to IL-2 as shown by in vitro incubation of pre-
treatment lymphocytes with IL-2. A lack of response is
therefore not due to lack of LAK cell precursors, although it
was not possible to test cytotoxicity against autologus
tumour. There was no significant correlation between clinical
outcome and NK or LAK cell induction, although the
patient with the highest NK value did show a complete
response. Further immunological clinical studies involving
IL-2 in combination with other cytokines are required.
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